OBJECTIVE: To report complete resolution of extensive conjunctival intraepithelial neoplasia in a patient treated with topical mitomycin C. METHODS: Based on clinical examination, impression cytology was performed on the corneal-conjunctival lesion. Management consisted of topical mitomycin 0.02%, administered four times a day for four 1-week cycles, with 1 week off between cycles. RESULTS: Complete resolution of the neoplasm was observed by slit lamp examination at 5 weeks of treatment, and histological resolution by 7 weeks of treatment. There were no complications due to the use of mitomycin. CONCLUSIONS: Topical mitomycin C 2 mg/ml (0.02%) may be a safe and effective treatment for conjunctival intraepithelial neoplasm prior to surgical removal.
OBJECTIVE: To report complete resolution of extensive conjunctival intraepithelial neoplasia in a patient treated with topical mitomycin C. METHODS: Based on clinical examination, impression cytology was performed on the corneal-conjunctival lesion. Management consisted of topical mitomycin 0.02%, administered four times a day for four 1-week cycles, with 1 week off between cycles. RESULTS: Complete resolution of the neoplasm was observed by slit lamp examination at 5 weeks of treatment, and histological resolution by 7 weeks of treatment. There were no complications due to the use of mitomycin. CONCLUSIONS: Topical mitomycin C 2 mg/ml (0.02%) may be a safe and effective treatment for conjunctival intraepithelial neoplasm prior to surgical removal.